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Abstract
Introduction
The prevalence of non-communicable diseases (NCDs) is rising in low- and middle-income
countries, including Kenya, disproportionately to the rest of the world. Our objective was to
quantify patient payments to obtain NCD screening, diagnosis, and treatment services in
the public and private sector in Kenya and evaluate patients’ ability to pay for the services.
Methods and findings
We collected payment data on cardiovascular diseases, diabetes, breast and cervical can-
cer, and respiratory diseases from Kenyatta National Hospital, the main tertiary public hospi-
tal, and the Kibera South Health Center—a public outpatient facility, and private sector
practitioners and hospitals. We developed detailed treatment frameworks for each NCD and
used an itemization cost approach to estimate payments. Patient affordability metrics were
derived from Kenyan government surveys and national datasets.
Results compare public and private costs in U.S. dollars. NCD screening costs ranged
from $4 to $36, while diagnostic procedures, particularly for breast and cervical cancer,
were substantially more expensive. Annual hypertension medication costs ranged from $26
to $234 and $418 to $987 in public and private facilities, respectively. Stroke admissions
($1,874 versus $16,711) and dialysis for chronic kidney disease ($5,338 versus $11,024)
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were among the most expensive treatments. Cervical and breast cancer treatment cost for
stage III (curative approach) was about $1,500 in public facilities and more than $7,500 in
the private facilities. A large proportion of Kenyans aged 15 to 49 years do not have health
insurance, which makes NCD services unaffordable for most people given the overall high
cost of services relative to income (average household expenditure per adult is $413 per
annum).
Conclusions
There is substantial variation in patient costs between the public and private sectors. Most
NCD diagnosis and treatment costs, even in the public sector, represent a substantial eco-
nomic burden that can result in catastrophic expenditures.
Introduction
The prevalence of non-communicable diseases (NCDs) is rising in low- and middle-income
countries (LMICs) disproportionate to the rest of the world. Currently, NCDs cause over 36
million annual deaths globally; 14 million of these are premature mortality (among those
younger than 70 years), and 90% of these premature deaths occur in LMICs [1]. Cancer, car-
diovascular disease, respiratory disease, and diabetes are the major causes of NCD deaths in
LMICs [2].
In Kenya, the mortality and morbidity from NCDs is rapidly increasing [3]. Cardiovascular
diseases are the leading cause of NCD mortality in Kenya because of the high prevalence of
multiple risk factors, including hypertension, diabetes, cholesterol, smoking, and obesity [4].
Multiple studies performed in selected populations across Kenya have identified a high preva-
lence of hypertension [4–6]. In the first nationally representative survey, performed in 2015
and which included hypertension measurement [7], hypertension was identified in 23.8% of
the respondents aged 18 to 69 years and 7% of those not on medication were diagnosed with
severe hypertension. Among those aged 18 to 44 years, 10.4% had three or more risk factors
for cardiovascular disease, and among those aged 45 to 69 years, 25.9% had three or more risk
factors.
Cancer is the second leading cause of NCD mortality, and the incidence of cancer increased
from 28,000 to 41,000 between 2008 and 2012 [8, 9]. The three leading cancer sites are the cer-
vix (40.1 cases per 100,000 individuals), the breast (38.3 cases per 100,000 individuals), and the
prostate (31.6 cases per 100,000 individuals) [9]. It is observed that most cancer cases are diag-
nosed at an advanced stage when curative treatment options are limited [10]. There is sparse
prevalence data on respiratory diseases—asthma and chronic obstructive pulmonary disease
(COPD). A systematic analysis estimated the prevalence of asthma in Africa as 12.8% (95%
confidence interval 8.2–17.1) in 2010 [11].
In response to the escalating burden of NCDs in Kenya, the government has established an
NCD division within the Ministry of Health. Kenya also launched a 5-year National NCD
Strategy in 2015 to guide the implementation of interventions to reduce the mortality from
NCDs. To operationalize this strategy, it is important to understand the cost of NCD health
services along the continuum of care, including those related to screening, diagnosis, and treat-
ment. Knowledge on the costs of NCD management is needed to identify cost-effective solu-
tions and prioritize interventions to address NCDs. Additionally, it is critically important to
Cost and affordability of non communicable disease health services
PLOS ONE | https://doi.org/10.1371/journal.pone.0190113 January 5, 2018 2 / 16
All data requests will be reviewed individually and
these data requests should be addressed to the key
contact for this study at the Kenya Ministry of
Health, Dr. Kibachio Joseph Mwangi (Head;
Division of Non-Communicable Diseases), who can
be reached via email at kibachiojoseph@gmail.
com.
Funding: RTI International, a non-profit research
institute, funded this study. Dr. Sujha
Subramanian’s time was partially funded by a US
National Institutes of Health grant
(1R01CA200845-01A1). The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
assess affordability of NCD services to evaluate patient access to required care. Individuals are
required to pay for health care services in the public sector in Kenya; the payments are subsi-
dized, but nevertheless, all services require some level of patient payments. Approximately half
of all the health facilities in Kenya are managed by either private for-profit or not-for-profit
organizations; therefore, a substantial proportion of health care is obtained in the private sec-
tor [12]. A minority if individuals in Kenya have health insurance coverage and almost all
employees in the formal sector, which is less than one-fifth of those employed, are covered
through the National Hospital Insurance Fund (NHIF). The NHIF provides payments for spe-
cific inpatient and outpatient services but not all costs in the private sector are covered and
therefore patients still incur out-of-pocket payments for health services. [13]
The objective of this study was to quantify patient payments for NCD screening, diagnosis,
and treatment services in the public and private sector in Kenya and evaluate patients’ ability
to pay for services along the continuum of care. We focused on the high-burden NCDs and
their risk factors, and we included cardiovascular diseases, diabetes, breast and cervical cancer,
and respiratory diseases in the assessment. These are the high prevalence diseases that the
World Health Organization is targeting to achieve a 25% relative reduction in the overall NCD
mortality by 2025 [1].
Methodology
We performed a comprehensive assessment of patient payments related to the four targeted
NCDs—cardiovascular disease, cancer, diabetes, and respiratory disease—we created a matrix
of relevant clinical services along the continuum of care of each disease or key risk factor. We
focused on risk factors and disease groupings for which there were comprehensive guidelines
for early detection and management. An additional key consideration was inclusion of the risk
factors and disease groups targeted in Kenya’s NCD strategic planning documents, including
the Kenya Health Policy 2014–2030 [14], the Kenya National Strategy for the Prevention and
Control of Non-Communicable Diseases 2015–2020 [15] and the National Cancer Control
Strategy 2011–2016 [8]. Table 1 provides a summary of the health services included in this
study.
Developing frameworks to identify services provided
We developed individual frameworks or treatment pathways for each health service identified
in Table 1. Each framework included, as appropriate, physician visits, diagnostic procedures,
laboratory tests, medications, and hospitalization. As a first step, the clinical pathways required
for each framework were developed through a detailed review of the published Kenya guide-
lines. These included the Clinical Management and Referral Guidelines (Volume III): Clinical
Guidelines for Management and Referral of Common Conditions at Levels 4–6 Hospitals
(2009) [16]; the Guidelines for Asthma Management in Kenya (2011) [17]; the National
Guidelines for Prevention and Management of Cervical, Breast and Prostate Cancers (2012)
[18]; the National Guidelines for Cancer Management Kenya (2013) [19]; the National Pallia-
tive Care Guidelines (2013) [20]; and the Non-Communicable Diseases Clinical Guidelines for
Clinical Officers and Nurse Task-Shifters (Me´decins Sans Frontières [MSF] Belgium and
Kenya Mission Kibera Project 2015, version 3.0) [21]. Second, to ensure that the guidelines
reflected real-world practice, the guideline-directed frameworks were presented to a wide
range of stakeholders, including clinicians from various specialties, such as doctors, nurses,
and pharmacists. These interactions with providers were also used to collect details on the
number of units of service typically required and estimates on the distribution of patients by
disease severity. We interviewed three cancer treatment specialists, two cancer screening
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specialists, one surgical nurse, one intensive care unit nurse, two cardiologists, three diabetes
management specialists, three palliative care specialists, one general NCD specialist, one
asthma and COPD specialist, and two ophthalmologists. As a third step, we reviewed pub-
lished literature [22–25] to confirm the itemization of services in the frameworks and the dis-
tribution of patients by severity or stage of disease (when clinical pathways differed by
severity). In the fourth and final step, we obtained data from literature, population-base
sources (for example, cancer registry) and clinic databases where available, on severity and
stage of disease. For breast and cervical cancer, we used data on cancer stage at diagnosis from
the Nairobi Cancer Registry. For hypertension, diabetes and asthma, we utilized data from the
provider sites and published literature [22–23] to represent the public sector and private prac-
titioner self-reported distribution in their practice for the private sector. For inpatient proce-
dures including cardiovascular treatments, we used information available in the published
literature supplemented with expert opinion [24,25]. The data from steps 2, 3 and 4 were used
to weight the individual costs by severity or stage of disease in order to estimate the weighted
average cost for the disease when applicable. This was performed to estimate average cost of a
disease, when applicable, as the cost of treatment differs by severity of the condition.
Estimating patient payments in the public and private sectors
We generally employed an itemization cost approach using standard economics methods [26–
27] to quantify patient payments for each clinical procedure or service using the frameworks.
The perspective employed in the cost estimation is that of the patient, as the objective is to esti-
mate patient payments for NCD services in the public and private sectors. For example, for
management of diabetes, the framework would include physician visits, cost of medications
and insulin when required, and any diagnostic procedures required for patient monitoring.
The number of each type of service required in any typical year was determined through con-
sultation with clinicians to estimate the cost for an annual period.
To reflect the public-sector payments, we collected data from Kenyatta National Hospi-
tal, the main tertiary referral hospital (level 6), located in Nairobi, with a capacity of 1,800
beds. Patient payments were obtained from the finance department for each service cate-
gory, including clinic visit cost, diagnostic tests, and procedures. The hospital’s main phar-
macy provided costs for the medicines. Patients pay the full acquisition cost of medications,
which are based on individual medication distributor prices with a mark-up of 10% on all
medication except cancer medicines with 0% mark-up, and a dispensing cost of U.S. $0.20
per prescription.
In addition to the standard public sector payments, we also collected costs that reflected
care provided in a quasi-public facility such as facilities run by faith-based organizations and
Table 1. Targeted diseases, risk factors, and medical services.
Screening Diagnosis Medication
Management
Treatments and Complications Included in Estimates
Hypertension X X X Complications including stroke, acute myocardial infarction, angina, heart failure,
chronic kidney disease, diabetic foot, and retinopathyDiabetes X X X
Cervical and Breast
Cancer
X X X Cancer treatment by stage at diagnosis
Asthma and
COPD
X X Hospital admissions for management of symptoms (acute episodes)
X indicates that the service was included in the cost estimation
https://doi.org/10.1371/journal.pone.0190113.t001
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international agencies. We selected MSF Belgium’s Kibera South Health Center (MSF-KSHC),
which served an informal settlement area in Nairobi, as an example of a quasi-public facility.
These institutions do not receive state funds but are private facilities that behave like public
facilities. The MSF facility, with approximately 500 outpatient visits daily, provided services
and medications free of charge. Other quasi-public facilities in Kenya though may charge
nominal payments for services provided. To reflect the payment that patients are likely to pay
at quasi-public, not-for-profit private clinics, we estimated the cost to provide care to patients
at the MSF-KSHC assuming payments would cover cost of operations to ensure sustainability
of services. We used an ingredient-based approach and estimated the cost of staff time, labora-
tory procedures, and medications using the frameworks described above as guidance for each
targeted medical service. Staff time was estimated by interviewing clinicians and direct obser-
vation of the staff engaged in patient interaction. Staff cost was calculated by multiplying time
expended by the hourly wage for each individual staff member. The unit costs for reagents
(ingredients) for laboratory procedures and medications were provided by the laboratory and
pharmacy managers respectively. At MSF-KSHC, we estimated the cost of hypertension, dia-
betes, and asthma management along with cervical cancer screening. Patients with complica-
tions were referred to Kenyatta National Hospital, and therefore, the same payments as those
paid by patients receiving services at Kenyatta National Hospital apply to other types of medi-
cal procedures.
For private sector payments, patient costs for visits, laboratory tests, diagnostic procedures,
and inpatient stays (basic ward bed) were obtained from private-sector practitioners (generally
two clinicians for each disease area) and hospitals at the same level as Kenyatta National Hos-
pital in terms of service provision (information was collected from two hospitals in Nairobi).
We used prices published in the Drug Index [28], which provides distributor prices for medi-
cation brands available in the Kenyan market, to estimate the cost of medications in the private
sector. We reviewed pharmacy retail prices (from stand-alone outlets and hospitals) for
selected medications and found them to be highly variable—both higher and lower than the
published Drug Index price list. Based on consultation with our medical experts, we used the
cost of commonly prescribed brands listed in the Drug Index. These prices were reviewed and
confirmed by the study team of clinicians, economists and health sector managers.
Microsoft Excel 2013 was used to develop the frameworks and compute the payment esti-
mates. The rows comprised various diagnostic examinations, laboratory tests, and treatments
for diseases, and the columns included other costing variables, such as estimated percentage of
patients receiving the intervention, the type of personnel providing the service, time taken to
provide the service, formulation and size of the product, frequency of dose per day and num-
ber of days the treatment was given, number of units necessary, cost per unit, and derived total
cost of the health service. Payment data were entered into the frameworks as applicable with
the aim of arriving at total costs of each diagnostic examination, test, or treatment. The unit
costs were multiplied by the number of units necessary for the full course of management or
treatment which generally included an annual period for outpatient care and complete inpa-
tient episode for hospital admissions. When there were differences in treatment by severity of
disease or type of patients, except opinion and data available from literature were used and an
estimated proportion of patients receiving each particular treatment algorithm was identified
to compute a weighted average total cost of management for the typical individual with the
condition. Using the same process, payments were estimated for NCD care in the public and
private sector. For the public sector, when applicable, we report the average (mean) cost for
outpatient patient management, combining estimates from Kenyatta National Hospital and
the MSF-KSHC facility. Most of the payment estimates were very similar; in a few cases, there
were large differences, which were mainly due to the variation in the type of diagnostic tests,
Cost and affordability of non communicable disease health services
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procedures, or medications used for patient management and their differential cost. Most of
the costs in the private sector were similar, expect for medications as indicated previously. All
costs were calculated in 2017 Kenyan Shillings and converted to U.S. dollar values (at 100
Kenya Shillings per U.S. dollar) for reporting. Cost data was collected from March 2016 and
October 2016. We only report patient payments in this study.
Generating affordability metrics
To assess affordability, we report key metrics on household expenditure, annual salary in the
formal sector, insurance coverage, and annual out-of-pocket payments for health care. These
estimates were derived from secondary data analysis of recent Kenyan national surveys
[13,29–32] and include data from the 2014 Kenya Demographic and Health Survey and the
2016 Kenya National Bureau of Statistics (KNBS) Economic Survey. We used previously devel-
oped analytic variables (no new variables were created for this study from these secondary data
sources; see references for details on methodology) and present estimates stratified by key
characteristics of interest. For example, we present insurance status by type of employment
based on whether person worked in the formal or informal sector. To fully explore potential
disparities by socioeconomic status, we report insurance status and catastrophic spending by
wealth quintiles (a quintile is 20% of the population). We used information from the 2013
Kenya Household Health Expenditure and Utilization Survey [31], and catastrophic spending
was defined as out-of-pocket spending greater than 40% of household non-food expenditure.
This study did not involve human subjects’ research. No patient level data was analyzed and
no identifiable information was collected. We obtained payment information from public and
private facilities and practitioners, analyzed data from reports published by the government of
Kenya and performed a review of the relevant literature. This study was approved by the Ken-
yan Ministry of Health and Kenyatta National Hospital.
Results
Screening and diagnosis of NCDs in Kenya
Table 2 presents estimated patient payments for screening procedures for early detection of
NCDs. These costs range from $3.90 to $10.50 in public facilities and $18.00 to $36.00 in pri-
vate facilities. Public-sector costs could be as low as $2.01, which is the cost of a health care
visit for many screening procedures. Screening can also be performed in combination with
other visits at potentially no additional cost to the patient; that is multiple services can be pro-
vided for a single visit fee. Pap smear for cervical cancer screening and random blood sugar for
diabetes screening cost more than the basic consultation payment, as they include laboratory
testing as well.
Diagnostic procedures are generally more expensive than screenings, while the cost of diag-
nosing cancers is substantially higher than screening for cancer. Cervical and breast cancer
diagnostic procedures are estimated as $181.38 and $401.00 in the public sector and $548.39
and $1,205.24 in the private sector. Patient payments for diagnosing diabetes and treatment
planning can also be a substantial outlay for the average Kenyan, with an estimated cost of
$41.95 in public facilities and $382.91 in private facilities.
Management of hypertension, diabetes, asthma, and COPD
Table 3 shows the estimated costs to patients with hypertension, diabetes, asthma, and COPD.
For hypertension, we categorized patients by the number of antihypertensive drugs prescribed
and whether resistant hypertension was present despite receiving standard medication
Cost and affordability of non communicable disease health services
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Table 2. Patient costs for screening and diagnosis of NCDs (2017 US dollars).
Public
Facilitiesa
(U.S. $)
Private
Facility
(U.S. $)
Screening
Breast cancer (clinical breast exam-CBE) 3.90 18.00
Cervical cancer—Visual Inspection with Acetic Acid/Lugols Iodine
(VIA/VILI)
3.90 –b
Cervical cancer—pap smear 10.50 25.00
Hypertension—2 or 3 blood pressure readings 8.52 36.00
Diabetes—random blood sugar 4.95 19.00
Diagnosis (when further evaluation after screening is required or when patients present with
symptoms)
Breast cancer 401.00 1,205.24
Cervical cancer 181.38 548.39
Hypertension 31.81 127.96
Diabetes 41.95c 382.91
Asthma 4.23 53.00
Chronic Obstructive Pulmonary Disease (COPD) 17.50 110.00
a Estimates are average (mean) cost at public hospital and low-cost quasi-public health clinic. Screenings
are done during a single visit.
b VIA is generally not offered in the private facilities in Nairobi, Kenya; VIA is provided only in government
and quasi-governmental facilities (for example, MSF and faith-based clinics)
c There is a wide range in costs of diabetes diagnosis due to the varied options and combinations of
laboratory tests routinely done at different facilities.
https://doi.org/10.1371/journal.pone.0190113.t002
Table 3. Patient costs for hypertension, diabetes, asthma and COPD management (2017 US dollars).
Public Facilitya Private Facilitya
Percentage of Patients U.S. $ Percentage of Patients U.S. $
Hypertension
Treatment—1 drug 20 25.64 5 418.20
Treatment—2 drug 35 67.25 70 596.44
Treatment—3 drug 25 81.20 15 948.06
Treatment—4 drug 10 110.33 – –
Treatment—resistantb 10 159.36 10 987.17
Diabetesc
Insulin only 32 186.40 10 541.22
Oral medication only 25 88.61 65 488.60
Both insulin and oral medication 43 234.44 25 675.85
Asthma
Mild 95 67.93d 95 295.45
Severe 5 146.74d 5 879.08
Chronic Obstructive Pulmonary Disease (COPD) 100 372.45 100 1,530.06
a The costs in this table include physician consultations for the average patient, medications, and admissions for managing symptoms (hypoglycaemia or
status asthmaticus). Major complications such as stroke are not included in this table;.
b Patient has high blood pressure despite the use of combination medications.
c The proportions reported in the public facilities are based on a recent study [21] while the proportions in the private facilities are based on expert opinion.
d There is a wide range in asthma management costs which reflects the variation in products, formulations, and brand-name medications used routinely at
different facilities. Approximately 5% of asthmatics have severe asthma and require specialized treatment administered at health facilities and even
admissions.
https://doi.org/10.1371/journal.pone.0190113.t003
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management. The distribution of patients is provided in this table, and the majority of the
patients were on two-drug therapy. We did identify differences in the distribution of patients
by number of hypertension medications; for example, the proportion on two-drug therapy
was 35% and 70% respectively in public and private facilities. Additionally, asthma patients
were categorized as mild or severe, and the pattern of distribution between these groupings
was similar in the public and private sector. Patient costs for care in public facilities ranged
from $25.64 to $372.45, and the range for private facilities was $295.45 to $1,530.06.
Cervical and breast cancer treatment
Table 4 presents patient costs for breast and cervical cancer treatment by stage at disease. The
cost includes all guideline-suggested treatments, including surgery, radiation, chemotherapy,
and hormonal therapy (for hormone receptor–positive breast cancer). Treatment for breast
cancer stages I and II followed similar clinical recommendations and therefore had the same
estimated cost. The costs of treating stage III breast and cervical cancer depended on whether
the treatment followed a curative approach or a palliative approach. The cost of treating cancer
generally increased by stage; the exception was some stage III and most stage IV cancers. Some
patients at this stage only receive non-curative palliative care and therefore incur a lower cost
than patients at stages with curative treatment. Public-sector patient cost for treating stage I,
II, and III breast cancer ranged from $1,340.38 to $1,542.58, and the cost for cervical cancer
ranged from $841.50 to $1,575.93. Breast and cervical cancer treatment in the private sector
was generally almost 10 times more expensive than in the public sector. Palliative care for a
6-month period was $169.20 and $752.43 in the public and private facilities respectively.
Managing common complications of hypertension and diabetes
Uncontrolled hypertension and diabetes can lead to serious complications that are very expen-
sive to manage. Table 5 summarizes the cost of some of the most common complications
requiring hospitalization, including strokes, acute myocardial infarction (heart attack), angina,
Table 4. Patient costs of cervical and breast cancer treatment (2017 US dollars).
Percentage of Patientsa Public Facility (U.S. $) Private Facility (U.S. $)
Breast Cancer Treatmentb
Stage I 7 1,340.38 10,914.45
Stage II 35 1,340.38 10,914.45
Stage III (curative approach) 19 1,542.58 11,862.36
Stage III (palliative approach) and Stage IV 40 675.35 8,569.87
Cervical Cancer Treatment
Stage 0 (carcinoma in situ) 1 85.50 257.25
Stage I 16 841.50 7,369.90
Stage II 36 962.50 7,669.90
Stage III (curative approach) 17 1,575.93 7,866.90
Stage III (palliative approach) and Stage IV 30 349.20 3,734.39
Palliative Carec 169.20 752.43
a Distribution of patients by stage was obtained from the Nairobi Cancer Registry.
b Hormonal therapy would follow the initial breast cancer treatment, depending on the tumor profile and patient characteristics. Tamoxifen cost was U.S.
$0.10 per day.
c Palliative care includes pain and symptom management as well as psychosocial support to the patients and their families. Patient payments for an
average duration of 6 months is presented.
https://doi.org/10.1371/journal.pone.0190113.t004
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and heart failure. The cost to patients ranged from $1,026.07 to $1,995.65 and $2,160.51 to
$16,710.82 in the public and private facilities, respectively. Chronic kidney disease requiring
dialysis would require annual payments of $5,338.00 in the public sector and $11,024.00 in the
private sector. Similarly, the cost for kidney transplant was $9,237.00 in the public center ver-
sus $19,724.00 in the private center. Diabetic foot care and retinopathy requiring outpatient
management were less than $100 per episode in the public sector and more than double that
cost in the private sector.
Affordability of screening, diagnosis, and treatment of NCDs in Kenya
Table 6 summarizes key health care affordability metrics, including annual household expen-
diture, average earnings in the formal sector, and insurance coverage. The estimated average
household expenditure per adult in 2013 was $412.80, $721.20 in the urban areas and $272.40
in rural settings [29]. The average earning per employee in the formal sector, which accounts
Table 5. Patient costs of managing complications of hypertension and diabetes (2017 US dollars).
Cost per Inpatient or Outpatient Episode
Public Facility (U.S. $) Private Facility (U.S. $)
Stroke 1,873.93 16,710.82
Acute myocardial infarction 1,995.65 12,529.47
Angina 1,236.81 10,740.44
Heart failure (secondary to hypertension) 1,026.07 2,160.51
Chronic kidney disease (dialysis)a—70% of patients 5,338.00 11,024.00
Chronic kidney disease (transplant)—30% of patients 9,237.00 19,724.00
Diabetic footb 69.95 731.99
Diabetic retinopathyb 94.45 242.68
a Dialysis costs includes an average of two sessions per week per patient for 1 year.
b Diabetic foot and diabetic retinopathy payments include one unilateral episode.
https://doi.org/10.1371/journal.pone.0190113.t005
Table 6. Health care affordability metrics in Kenya (2017 US dollars).
Measure Estimate Year of Data Data Source
Annual Household Expenditure per Adult (U.S. $)
Average 412.80 2013
(year
published)
KNBS and Society for International Development [29]
Urban (31.2% of the population) 721.20
Rural (68.8% of the population) 272.40
Average Annual Earning per Employee in the Formal Sector (U.S. $)
Private 5,952.12 2015 KNBS Economic Survey [30]
Public 6,264.09
Health Insurance Coverage (%)
Overall (15–49 years) 18% of women, 21% of
men
2014 Kenya Demographic & Health Survey, [13]
NHIF 14% of women, 18% of
men
Employer-based coverage 2% of women, 3% of men
NHIF—Formal sector (17% of
workforce)
98% coverage for this
workforce
2014 U.S. Agency for International Development (USAID) and Health
Finance & Governance, [33]
NHIF—Informal sector (83% of
workforce)
16% coverage for this
workforce
https://doi.org/10.1371/journal.pone.0190113.t006
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for about 17% of the total employment, was approximately $6,000 annually in 2016 [30]. Most
Kenyans aged 15 to 49 years do not have health insurance (82% of women, 79% of men).
There is almost universal health insurance coverage among those employed in the formal sec-
tor, whereas less than one-fifth of those working in the informal sector have coverage [33].
Among those with health insurance, most are covered by the NHIF [13], and a very small pro-
portion receives employer-based insurance [33].
Fig 1 shows the proportion with health insurance and catastrophic spending by wealth quin-
tiles. There is a consistent inverse relationship between health insurance coverage and cata-
strophic health expenditure. Those in the poorest quintile had the lowest proportion with health
insurance (2.9%), and those in the wealthiest quintile had the highest proportion (41.5%). Con-
versely, the poorest individuals had the largest proportion of catastrophic spending (8.7%), and
the wealthiest individuals had the lowest proportion (3.8%) [31]. It is interesting to note that in
Fig 1. Catastrophic health expenditure: Out-of-pocket spending 40% of household non-food
expenditure. Source: 2013 Kenya Household Health Expenditure and Utilization Survey [31].
https://doi.org/10.1371/journal.pone.0190113.g001
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each of the wealth quintiles, at least some households experienced catastrophic health expendi-
ture; the poor are disproportionally impacted, but the wealthy can be vulnerable to financial col-
lapse as a result of high health expenditures as well. On average, medication management for
hypertension (2 drug combination) or diabetes would require about 1%-2% and 8%-10% of the
average annual income (reported in Table 6) respectively in the public and private sectors. For
curative breast cancer treatment, approximately one-fifth of the annual income will be required
for care in public facilities and more than 1.5 times the annual income for care in private
facilities.
Discussion
Cost and affordability are key emerging issues in addressing the burden posed by NCDs in
LMICs. In this paper, we report on patient payments required for obtaining health care ser-
vices in Kenya along the continuum of care from screening, to diagnosis, to treatment in pub-
lic- and private-sector facilities. Screening costs were generally inexpensive, with many tests
available for about $4. The costs of diagnostic procedures for follow-up of abnormal screening
results, though, were substantially higher. For example, payments for breast cancer diagnosis
were on average $401 in public facilities and $1,205 in private facilities. The payments required
to undergo many diagnostic tests, specifically those related to cancer and diabetes, are beyond
the reach of the average Kenyan, as the annual household expenditure per adult is about $413.
Overall, the payments for screening and diagnosis were consistently lower in public-sector
than private-sector facilities, but even these subsidized costs are likely to pose access barriers to
the majority of Kenyans.
Management of hypertension, diabetes, and asthma required modest payments in the pub-
lic sector, ranging from $26 to $234. These payments are far more affordable than the charges
in private facilities, which ranged from $418 to $987. Inpatient treatments required substan-
tially higher payments. Patient payment for breast and invasive cervical cancer treatment in
the public sector was about $1,000 but more than $7,000 in the private sector. Stroke admis-
sions ($1,874 versus $16,711) and annual cost of dialysis for chronic kidney disease ($5,338
versus $11,024) were among the most expensive treatments. Kidney transplants would have a
very high initial cash outlay but potentially more cost effective in the long run.
There is very limited information on cost of NCD treatments in Sub-Saharan Africa that
can be used to compare the findings from this study [34–37]. One study from South Africa
reported stroke management cost of $16,993 [34] which is very similar to the cost of $16,711
reported in the private sector in this study. Another study from Sudan estimated kidney trans-
plantation to cost $18,132 while our estimates range from about $9,000 in the public facilities
to $20,000 in the private facilities [35]. An evaluation of diabetes foot ulcer treatment in Nige-
ria [36] reported a total cost of $1,619 for the entire course of management while in this study
we report costs of about $70 and $732 for public and private facilities respectively for a single
episode of care. These estimates are not directly comparable as the reason for the higher cost
in the Nigerian study is because their estimates include multiple episodes and the cost of foot
amputation (for a proportion of patients requiring this), which is not included in this study.
Overall, the findings from our study mirror past cost estimates from Sub-Saharan Africa but
differences between the types of procedures and follow up periods included in the studies
make systematic comparisons of cost estimates difficult to perform.
The health insurance information presented in this study show that most Kenyans are not
covered [32]; therefore, they have to use savings or borrow funds to pay for health care. In
2014, approximately 20% had health insurance coverage through the NHIF; there are ongoing
efforts to increase NHIF enrollment but nevertheless a large proportion of the population
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remains uninsured. [38] The fund provides coverage for several types of high-cost diagnostic
tests and treatments, including $80 for a CT scan, $150 for an MRI, $250 per chemotherapy
session, $36 per radiotherapy session, and up to $1,300 for surgeries. In general, NHIF pay-
ments will cover inpatient admissions for NCDs and specific diagnostic tests at capped rates.
NHIF currently do not cover most medication costs, many diagnostic tests, costs of managing
complications, and palliative care (for example, costs of chemotherapy ports and stoma bags).
The low rate of health insurance coverage and high cost of many NCD treatments may
result in health care disparities in Kenya. Poor households are far more likely not to have
health insurance and are also more likely to experience catastrophic health expenditure com-
pared with wealthy households. The statistics reported in this manuscript on catastrophic
expenditure reflect all health care costs. The gap between the rich and poor is likely to increase,
as the burden from NCDs is projected to grow across all socioeconomic groups because of the
high prevalence of risk factors [7]. Additionally, NCDs are expected to result in overall higher
household financial burden; a recent study reported that although general illnesses reduce
household income by 13.63%, NCDs reduce household income by 28.64% [39]. An increase in
health insurance coverage among those in the informal sector can help offset some of this
anticipated financial burden. Workers in the informal sector have been encouraged to make
voluntary contributions to NHIF in monthly installments of $5 or annual contributions of
$60 per family. The current low levels of voluntary contributions need to be systematically
explored, and research is needed to better understand barriers to obtaining health insurance
coverage.
Currently, screening for cervical and prostate cancers is a covered service by NHIF, but the
public awareness of this benefit is unknown as there are no specific studies on this issue. Evalu-
ating the current level of knowledge and adopting policies, such as systematic patient and pro-
vider education, to increase awareness of the inclusion of screening within the basic benefit
package would be essential to reduce the burden from NCDs. Most NCDs are not diagnosed at
an early stage, and screening should be implemented for other NCDs, including hypertension,
diabetes and breast cancer, to identify risk conditions and diseases early, when treatments are
more effective. Early detection of NCDs and prompt management is key to mitigate the high
cost of advanced disease and complications. To encourage compliance with follow-up recom-
mendations, any coverage provided for screening should also include follow-on diagnostic
tests and medication management. A recent national survey reported that only 22% of those
diagnosed with high blood pressure were taking the medications prescribed by a health worker
[7]. Reducing financial barriers may encourage more individuals to comply with provider rec-
ommendations. In addition to screening and diagnosis, prevention of NCDs should be priori-
tized. The World Health Organization has identified several highly cost-effective initiatives,
including interventions to increase physical activity, promote healthier diets, reduce tobacco
use, and eliminate harmful use of alcohol [1]. These lifestyle changes should be vigorously pro-
moted to reduce incidence of NCDs and research should be undertaken to identify the best
approaches to implement these health promotion behaviors. Prevention is important as it can
potentially reduce the burden from NCDs and the related cost of financing high-cost NCD
inpatient treatments.
In Kenya, NCD services are provided in both the public and private sectors, but the pay-
ments required for services differ substantially. The public sector is subsidized through gov-
ernment payments, and therefore, it is expected to provide care at lower cost to patients.
However, no systematic comparison of the quality of the services provided in private and pub-
lic facilities is available to assess the value of the care provided. Past research exploring quality
of care and access in the public and private health sectors in LMICs has highlighted the com-
plexity of such comparisons due to methodological challenges and wide variation across
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providers [40–43]. In Kenya, this is certainly also the case, as the public sector requires lower
patient payments but, in some instances, does not provide all the required NCD services or
procedures (for example, hormone receptor status testing and percutaneous coronary angio-
plasty). There also may be long waiting lists for NCD treatments. The private sector requires
higher payments but may offer more comprehensive and timely management of NCDs. We
need to better understand the role of public- and private-sector facilities in delivering NCD
health services in Kenya, and this will require better data collection to assess the quality of the
care provided.
The payments reported in this study represent the average cost to patients to obtain NCD
health care services in the public- and private-sector facilities. A potential limitation of this
study is that patient payments, especially in the private sector, can vary based on the type of
provider, location, and other factors. There may also be variability in the payments required at
different levels of public facilities, for example tertiary versus district level. We report the esti-
mated patient payments as we did not collect actual payments made by individual patients.
Furthermore, we report payments made by patients to evaluate affordability and not the “true
cost” of providing the services as payments include varying levels of mark-ups in the private
sector and subsidies in the public sector. Cost of medications in the private sector is based on
information available in the Drug Index and large variation in medication prices exist across
pharmacies. Drug Index are wholesale or distributor prices and therefore some patients may
be paying more than the estimated price while others may be paying less, due to variations in
mark-ups and medicine procurement practices across pharmacies. In addition, the payments
reported for inpatient admissions represents the initial episode of care and does not systemati-
cally account for all post-discharge complications, long-term disabilities, and comorbidities
related to the treatments. Additionally, non-medical costs borne by patients to receive required
health care services are not included. These costs could be substantial for patients who have to
travel to tertiary care centers to receive specialized treatment for NCDs. Furthermore, the cost
estimates do not include loss of income due to disabilities and the time required for treat-
ments. Therefore, the true cost to patients who undergo NCD treatments is likely to be much
higher than the health care payments presented in this study.
Conclusion
In Kenya, the high cost of NCD treatment and low rate of health insurance coverage signifi-
cantly limits affordability for most of the population. In the short term, efforts should be made
to increase insurance coverage among those employed in the informal sector, but at the same
time, prevention and screening interventions should be prioritized to reduce the financial bur-
den to the nation as a whole. NCD health care services are provided in both the private- and
public-sector facilities in Kenya, and the value of these services, benefit gained for the cost
expended, should be systematically assessed in future studies.
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